It sounds like the plan is to use the Medipharm Labs CBD oil...

It sounds like the plan is to use the Medipharm Labs CBD oil that has been exported as resin (this is generic so non-proprietary, i.e. no Intellectual Property) and formulate this into a hard shell capsule.

So where is the value?

There are very sophisticated cannabis manufacturing companies (Medipharm labs, Valens, Radient, Neptune) which have been making different drug delivery technologies. There are hundreds (water soluble CBD, gelcaps, soft-shell, liquid, suspension etc etc) and they are ultra-low cost.

If this is the sole value proposition of Auscann which is what the webinar appears to suggest, and they have not lodged any patents (there were none disclosed) then I can not see any value in Auscann's business plan whatsover.